NEW YORK, March 22, 2024 – Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for EMBLAVEO® (aztreonam-avibactam) in the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.
NEW YORK, N.Y., February 23, 2024 – Pfizer Inc. (NYSE:PFE) announced today that, for the fifth consecutive year, an independent compensation expert confirmed equitable pay practices for employees at Pfizer.
The study assessed pay equity for gender worldwide and for minorities in the United States based on compensation data, including base pay and bonuses. The study measured the difference between similar groups of employees when adjusting for factors such as role, grade, job level, and location.
Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC®) protein degrader designed to target and degrade the estrogen receptor (ER) protein